Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357487 | 1.00 | IDO1 (0.57) | IDO1SIGMAR1TSHRADRA2AADRA1A | |
| SCHEMBL6784204 | 0.96 | IDO1 (0.53) | IDO1SIGMAR1 | |
| SCHEMBL18440245 | 0.89 | SIGMAR1 (0.54) | IDO1SIGMAR1LMNA | |
| SCHEMBL6542312 | 0.87 | SIGMAR1 (0.56) | IDO1SIGMAR1 | |
| SCHEMBL10785005 | 0.87 | SIGMAR1 (0.60) | IDO1SIGMAR1 | |
| SCHEMBL4661810 | 0.86 | SIGMAR1 (0.63) | IDO1SIGMAR1 | |
| SCHEMBL21924071 | 0.86 | SIGMAR1 (0.63) | IDO1SIGMAR1 | |
| SCHEMBL6542145 | 0.86 | SIGMAR1 (0.63) | IDO1SIGMAR1 | |
| SCHEMBL30285859 | 0.86 | SIGMAR1 (0.63) | IDO1SIGMAR1 | |
| SCHEMBL11671198 | 0.85 | SRD5A1 (0.55) | IDO1SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022217-B2 | Compounds suitable as modulators of HDL | CADILA HEALTHCARE LIMITED (IN) | 2011-09-20 | — | — | US | claimed |
| JP-6122644-A | — | — | None | — | — | JP | disclosed |
| JP-61004796-A | — | — | None | — | — | JP | disclosed |
| JP-10059900-A | — | — | None | — | — | JP | disclosed |
| US-11655368-B2 | Condensation curable composition comprising siloxane-imide crosslinker | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3484842-B1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11020730-B2 | Halogen-containing metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190314799-A1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-17 | — | — | US | disclosed |
| EP-3484842-A1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | Massachusetts Institute of Technology (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018013943-A1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-0614902-B1 | Phosphine compounds and transition metal-phosphine complexes containing them as ligands | TAKASAGO PERFUMERY CO LTD (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5530150-A | HAVING PHOSPHINE AND PHOSPHITE GROUPS IN SAME MOLECULE; CATALYST SELECTIVITY | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-06-25 | — | — | US | disclosed |
| WO-1995033765-A1 | CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED PEPTIDE ANALOG | PEPTOR LTD. (IL) | 1995-12-14 | — | — | WO | disclosed |
| EP-0479542-B1 | A phosphino binaphthyl compound and transition metal complexes thereof | TAKASAGO PERFUMERY CO LTD (JP) | 1995-11-29 | — | — | EP | disclosed |
| EP-0614902-A1 | Phosphine compounds and transition metal-phosphine complexes containing them as ligands | Takasago International Corporation (JP) | 1994-09-14 | — | — | EP | disclosed |
| JP-H06122644-A | BI@(3754/24)TETRAHYDRONAPHTHYL) DERIVATIVE AND ITS PRODUCTION | KANKYO KAGAKU CENTER:KK | 1994-05-06 | — | — | JP | disclosed |
| US-5206399-A | 2,2'-BIS(DIPHENYLPHOSPHINO)-5,5',6,6',7,7',8,8'-OCTAHYDRO-1,1'-BINAPHTHYL AND TRANSITION METAL COMPLEX CONTAINING THE SAME AS LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-04-27 | — | — | US | disclosed |
| EP-0479542-A1 | A phosphino binaphthyl compound and transition metal complexes thereof | Takasago International Corporation (JP) | 1992-04-08 | — | — | EP | disclosed |
| JP-S614796-A | PRODUCTION OF SYNTHETIC LUBRICATING OIL | IDEMITSU KOSAN CO LTD | 1986-01-10 | — | — | JP | disclosed |
| US-4521324-A | Fluid for traction drive | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1985-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314799-A1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | ZRANB2, SLC39A3, ZCCHC8 | IDO1 1928/4885SIGMAR1 1944/4885TSHR 2418/4885 |
| US-11020730-B2 | Halogen-containing metathesis catalysts and methods thereof | ZRANB2, SLC39A3, ZCCHC8 | IDO1 1928/4885SIGMAR1 1944/4885TSHR 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.